



IFW

Dkt. 2799/75219-PCT-US

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

Applicants : MEIJER, Christophorus et al.
U.S. Serial No. : 10/551,584
U.S. Filed on : September 29, 2005
In connection with
Int'l. App. No. : PCT/NL2004/000118
Int. Filing Date : February 17, 2004
For : DETECTION FOR HPV-INDUCED INVASIVE CANCERS
AND THEIR PRECURSOR LESIONS WITH INVASIVE
POTENTIAL

COOPER & DUNHAM LLP
1185 Avenue of the Americas
New York, NY 10036

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to applicants' duty of disclosure, applicants wish to call to the attention of the Examiner in charge of the above-identified application the references listed on the enclosed forms PTO/SB/08A and PTO/SB/08B, copies of which are provided herewith. The Examiner is respectfully requested to review the reference and make them of record in the application.

Applicants: MEIJER, Christophorus et al.
U.S. Serial No.: 10/551,584
Based on Int'l. Serial No.: PCT/NL2004/000118
Page 2

The Commissioner is hereby authorized to charge any additional fee required in connection with the filing of this Information Disclosure Statement to Deposit Account 03-3125.


Respectfully submitted,


Dated: August 9, 2006

By: 

Robert D. Katz – Reg. No. 30,141
COOPER & DUNHAM LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Attorney for Applicants

I hereby certify that this paper is being deposited this date with the U.S. Postal Service as first class mail addressed to: Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450	
 Robert D. Katz Reg. No. 30,141	Date 8/9/06



PTO/SB/08A (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **1** of **2****Complete if Known**

Application Number	10/551584
Filing Date	Feb. 17, 2004
First Named Inventor	Meijer, Christophorus
Art Unit	
Examiner Name	
Attorney Docket Number	75219/RDK

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 6596493 B1	07/22/2003	REEVES	
		US- 6355424 B1	03/12/2002	LORINCZ	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 02/14557 A	02/21/2002	REEVES		
		WO 992980	06/17/1999	LORINCZ		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/551584		
		Filing Date	Feb. 17, 2004		
		First Named Inventor	Meijer, Christophorus		
		Art Unit			
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	75219/RDK

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LIST HEINZ-JOACHIM ET AL.: "Methylation sensitivity of the enhancer from the human papillomavirus type 16" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, n. 16, 1994, pages	
		(cont'd from above) 11902-11911	
		PULIDO HUGO ARIAS ET AL.: "Identification of a 6-cM minimal deletion at 11q23.1-23.2 and exclusion of PPP2R1B gene as a deletion target in cervical cancer" CANCER RESEARCH,	
		(cont'd from above) vol. 60, no. 23, 1 December 2000 (200-12-01), pages 6677-6682	
		FUKUHARA HIROSHI ET AL.: "Promoter methylation of TSLC1 and tumor supression by its gene product in human prostate cancer" JAPANESE JOURNAL OF CANCER RESEARCH, vol. 93, no. 6,	
		(cont'd from above) June 2002 (2002-060, PAGES 605-609	
		STEENBERGEN RENSKE D M ET AL.: "TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia." JOURNAL OF THE NATIONAL CANCER INSTITUTE, 18 February 2004, vol.	
		(cont'd from above) 96, no. 4, 18 February 2004 (2004-02-18), pages 294-305	
		INTERNATIONAL SEARCH REPORT	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.